ReviewThe European journal of neuroscience2026
Antibody-Mediated Mechanisms in Autoimmune Neurological Disorders.
Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibody-Mediated Mechanisms in Autoimmune Neurological Disorders.The European journal of neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibody-mediated encephalitides are a rapidly evolving class of disorders in which autoantibodies against neuronal surface proteins disrupt synaptic function, neural circuits and cognition. This article summarizes the presentations and discussions from a symposium at the 2025 meeting of the Spanish Society of Neuroscience (SENC). Rather than providing a comprehensive review of autoimmune encephalitis, we highlight selected advances that illustrate how antibody-mediated mechanisms contribute to neurological dysfunction, using anti-NMDAR encephalitis as a paradigmatic example. Specifically, we contrast experimental approaches that have shaped current understanding of disease pathogenesis, including in vitro systems, passive-transfer mouse models and active immunization paradigms that capture B-cell responses, intrathecal immunity, microglial engagement and relapse biology. We also examine emerging evidence that antibody Fc features, including subclass and glycosylation, contribute to innate immune activation and clinical heterogeneity, with examples linking proinflammatory Fc signatures to poorer outcomes. Finally, we review selected studies addressing behavioural and cognitive consequences in animal models and patients, particularly long-lasting deficits in working memory, and discuss therapeutic implications ranging from synapse-stabilizing strategies and NMDAR positive allosteric modulators to B-cell-targeting treatments and approaches aimed at modulating Fc-dependent pathways. Together, these findings suggest that integrating molecular immunoprofiling with systems neuroscience may improve prognostic accuracy and inform therapies that restore immune homeostasis and functional circuit recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.